SANTA MONICA, Calif.--(BUSINESS WIRE)--Nov 17, 2025--
GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced two major initiatives to make FDA-approved GLP-1 medications more widely available. First, the launch of GoodRx for Weight Loss, a telemedicine subscription that connects consumers to licensed healthcare providers for affordable weight management treatment. Second, in partnership with Novo Nordisk, a new introductory cash price of $199 per month for Ozempic® (semaglutide) and Wegovy® (semaglutide) injection pens, available to GoodRx users.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117268209/en/
“GoodRx is scaling a consumer-first model for affordable GLP-1 treatment,” said Wendy Barnes, President and CEO of GoodRx. “We’re committed to connecting consumers with FDA-approved GLP-1 medications backed by science and safety, not compounded alternatives that fall short of those standards. By uniting nationwide pharmacy integration, home delivery capabilities, and transparent pricing in one seamless experience, GoodRx is creating a higher standard for affordability and trust in weight loss care.”
A Seamless Path to Safe, FDA-Approved GLP-1 Treatment for Weight Loss
GoodRx for Weight Loss is a comprehensive, direct-to-consumer telemedicine subscription built to simplify every step of the GLP-1 treatment journey, from consultation to prescription to fulfillment.
GoodRx for Weight Loss features include:
The GoodRx for Weight Loss telemedicine subscription is available for an introductory rate of $39 per month through January 2026, with a standard price of $119 beginning on February 1, 2026. Medications are priced separately, allowing customers to only pay for what they need.
Delivering Real Savings on the Most Trusted GLP-1 Medications
Building on its collaboration with Novo Nordisk, GoodRx is now offering savings on Ozempic and Wegovy injection pens to first-time GoodRx users for an introductory price of $199 per month for the first two fills of the two lowest doses (0.25 mg and 0.5 mg), followed by an ongoing price of $349 per month for subsequent fills.* This new reduced pricing makes two of the most in-demand GLP-1 treatments more affordable and accessible for eligible self-paying patients at nearly all pharmacies nationwide.
Whether a consumer already has a prescription or needs help getting started, GoodRx provides a simple, straightforward path to treatment:
Together, these initiatives reinforce GoodRx’s leadership in making trusted, science-backed GLP-1 treatments more affordable and easier to obtain. As the nation’s leading platform for prescription savings, GoodRx is redefining what consumer-first healthcare looks like, delivering safe, affordable, and scalable solutions that help more people start and stay on effective treatment.
*Offer valid through March 31, 2026. Patients using GoodRx to save on their Ozempic or Wegovy prescription for the first time can pay just $199 per month for the first two fills. This introductory price applies to the two lowest doses (0.25 mg and 0.5 mg). After the initial two months, patients will move to the new standard monthly price of $349 per month. Self-pay cost for Ozempic 2.0 mg remains $499.
About GoodRx
GoodRx is the leading platform for medication savings in the U.S., used by nearly 30 million consumers and over one million healthcare professionals annually. Uniquely situated at the center of the healthcare ecosystem, GoodRx connects consumers, healthcare professionals, payers, PBMs, pharma manufacturers, and retail pharmacies to make saving on medications easier. By reducing friction and inefficiencies, GoodRx helps consumers save time and money when filling prescriptions so they can get the care they deserve. Since 2011, GoodRx has helped Americans save over $85 billion on the cost of their medications.
GoodRx periodically posts information that may be important to investors on its investor relations website athttps://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.
GoodRx Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding anticipated consumer savings, convenience and accessibility; the expected benefits and value of GoodRx for Weight Loss; and our plans, expectations and objectives. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits; changes in medication pricing and pricing structures; our reliance on a limited number of industry participants; and the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, and our other filings with the SEC. Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
GoodRx Launches New $39 Per Month Weight Loss Telemedicine Subscription, Unveils Industry-Leading Introductory Cash Price of $199 Per Month for Ozempic® and Wegovy®
GoodRx for Weight Loss
